REFERENCES
1. Mauvais-Jarvis F. Gender differences in glucose homeostasis and diabetes. Physiol Behav. 2018;187:20-3.
2. Memaj P, Jornayvaz FR. Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology. Front Endocrinol. 2022;13:1031633.
3. Vries M, Westerink J, Kaasjager KHAH, de Valk HW. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105:3842-53.
4. Shi Y, Wang Q, Sun Y, et al. The prevalence of lean/nonobese nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2020;54:378-87.
5. Ryk A, Łosiewicz A, Michalak A, Fendler W. Biological activity of c-peptide in microvascular complications of type 1 diabetes-time for translational studies or back to the basics? Int J Mol Sci. 2020;21:9723.
6. Wahren J, Larsson C. C-peptide: new findings and therapeutic possibilities. Diabetes Res Clin Pract. 2015;107:309-19.
7. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care. 2009;32:1244-9.
8. Quattrin T, Haller MJ, Steck AK, et al; T1GER Study Investigators. Golimumab and beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med. 2020;383:2007-17.
9. Herold KC, Delong T, Perdigoto AL, Biru N, Brusko TM, Walker LSK. The immunology of type 1 diabetes. Nat Rev Immunol. 2024;24:435-51.
10. Bazile C, Abdel Malik MM, Ackeifi C, et al. TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial. Front Immunol. 2024;15:1470677.
11. Vries SAG, Verheugt CL, Mul D, Nieuwdorp M, Sas TCJ. Do sex differences in paediatric type 1 diabetes care exist? Diabetologia. 2023;66:618-30.
12. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39:481-97.
13. Agarwal S, Kanapka LG, Raymond JK, et al. Racial-ethnic inequity in young adults with type 1 diabetes. J Clin Endocrinol Metab. 2020;105:e2960-9.
14. Shepard BD. Sex differences in diabetes and kidney disease: mechanisms and consequences. Am J Physiol Renal Physiol. 2019;317:F456-62.
15. Giandalia A, Giuffrida AE, Gembillo G, et al. Gender differences in diabetic kidney disease: focus on hormonal, genetic and clinical factors. Int J Mol Sci. 2021;22:5808.
16. Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62:1550-60.
17. Chase-Vilchez AZ, Chan IHY, Peters SAE, Woodward M. Diabetes as a risk factor for incident peripheral arterial disease in women compared to men: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19:151.
18. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57:1542-51.
19. Wang Y, O'Neil A, Jiao Y, et al. Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants. BMC Med. 2019;17:136.
20. Wei G, Zhu JJ, Shen FJ, et al. Heterogeneous metabolic changes of brown and white adipose tissues are associated with metabolic adaptations in periparturient mice. J Mol Endocrinol. 2024;73:e240012.
21. Frias JP, Macaraeg GB, Ofrecio J, Yu JG, Olefsky JM, Kruszynska YT. Decreased susceptibility to fatty acid-induced peripheral tissue insulin resistance in women. Diabetes. 2001;50:1344-50.
22. Nuutila P, Knuuti MJ, Mäki M, et al. Gender and insulin sensitivity in the heart and in skeletal muscles: studies using positron emission tomography. Diabetes. 1995;44:31-6.
23. Brener A, Hamama S, Interator H, et al. Sex differences in body composition in youth with type 1 diabetes and its predictive value in cardiovascular disease risk assessment. Diabetes Metab Res Rev. 2023;39:e3584.
24. Schweiger D, Battelino T, Groselj U. Sex-related differences in cardiovascular disease risk profile in children and adolescents with type 1 diabetes. Int J Mol Sci. 2021;22:10192.
25. Braffett BH, Bebu I, El Ghormli L, et al; DCCT/EDIC Research Group. Cardiometabolic risk factors and incident cardiovascular disease events in women vs men with type 1 diabetes. JAMA Netw Open. 2022;5:e2230710.
26. Nyström L, Dahlquist G, Ostman J, et al. Risk of developing insulin-dependent diabetes mellitus (IDDM) before 35 years of age: indications of climatological determinants for age at onset. Int J Epidemiol. 1992;21:352-8.
27. Blohmé G, Nyström L, Arnqvist HJ, et al. Male predominance of type 1 (insulin-dependent) diabetes mellitus in young adults: results from a 5-year prospective nationwide study of the 15-34-year age group in Sweden. Diabetologia. 1992;35:56-62.
28. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46:760-5.
29. Harjutsalo V, Maric-Bilkan C, Forsblom C, Groop PH. Impact of sex and age at onset of diabetes on mortality from ischemic heart disease in patients with type 1 diabetes. Diabetes Care. 2014;37:144-8.
30. Bisson A, Bodin A, Fauchier G, et al. Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. Cardiovasc Diabetol. 2021;20:24.
31. Tas E, Vu BK, Mendizabal B, Libman I, Muzumdar R. Relationship between liver and cardiometabolic health in type 1 diabetes. Front Endocrinol. 2024;15:1505430.
32. Rakusanova S, Cajka T. Metabolomics and lipidomics for studying metabolic syndrome: insights into cardiovascular diseases, type 1 & 2 diabetes, and metabolic dysfunction-associated steatotic liver disease. Physiol Res. 2024;73:S165-83.
33. Boulos M, Mousa RS, Jeries N, et al. Hidden in the fat: unpacking the metabolic tango between metabolic dysfunction-associated steatotic liver disease and metabolic syndrome. Int J Mol Sci. 2025;26:3448.
34. Bourganou MV, Chondrogianni ME, Kyrou I, et al. Unraveling metabolic dysfunction-associated steatotic liver disease through the use of omics technologies. Int J Mol Sci. 2025;26:1589.
35. Wang JS, Yen FS, Lin KD, Shin SJ, Hsu YH, Hsu CC; Diabetes Kidney Disease Research Committee of the Diabetes Association of the Republic of China (Taiwan). Epidemiological characteristics of diabetic kidney disease in Taiwan. J Diabetes Investig. 2021;12:2112-23.
36. Lord S, Greenbaum CJ. Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes. F1000Res. 2020;9:827.
38. Im SS, Kang SY, Kim SY, et al. Glucose-stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding protein-1c in the hepatocytes. Diabetes. 2005;54:1684-91.
39. Thorens B, Flier JS, Lodish HF, Kahn BB. Differential regulation of two glucose transporters in rat liver by fasting and refeeding and by diabetes and insulin treatment. Diabetes. 1990;39:712-9.
40. Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019;1:312-28.
41. Manco M. Insulin resistance and NAFLD: a dangerous liaison beyond the genetics. Children. 2017;4:74.
42. Petta S, Gastaldelli A, Rebelos E, et al. Pathophysiology of non alcoholic fatty liver disease. Int J Mol Sci. 2016;17:2082.
43. Mertens J, De Block C, Spinhoven M, Driessen A, Francque SM, Kwanten WJ. Hepatopathy associated with type 1 diabetes: distinguishing non-alcoholic fatty liver disease from glycogenic hepatopathy. Front Pharmacol. 2021;12:768576.
44. Mohamed J, Nazratun Nafizah AH, Zariyantey AH, Budin SB. Mechanisms of diabetes-induced liver damage: the role of oxidative stress and inflammation. Sultan Qaboos Univ Med J. 2016;16:e132-41.
45. Rafaqat S, Sattar A, Khalid A, Rafaqat S. Role of liver parameters in diabetes mellitus - a narrative review. Endocr Regul. 2023;57:200-20.
46. West J, Brousil J, Gazis A, et al. Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. QJM. 2006;99:871-6.
47. Huo G, Gao Y. Type 1 diabetes and combined acute and chronic complications are associated with risk of progression of liver fibrosis: a Mendelian randomization study. Front Endocrinol. 2024;15:1302611.
48. Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407-18.
49. Donaghue K, Jeanne Wong SL. Traditional cardiovascular risk factors in adolescents with type 1 diabetes mellitus. Curr Diabetes Rev. 2017;13:533-43.
50. Della Pepa G, Lupoli R, Masulli M, et al. Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes. J Endocrinol Invest. 2024;47:2371-8.
51. Caldara R, Tomajer V, Monti P, et al. Allo beta cell transplantation: specific features, unanswered questions, and immunological challenge. Front Immunol. 2023;14:1323439.
52. Zhou A, Webb G, Zhu X, Steiner DF. Proteolytic processing in the secretory pathway. J Biol Chem. 1999;274:20745-8.
53. Chima RS, Maltese G, Lamontagne T, et al. C-peptide ameliorates kidney injury following hemorrhagic shock. Shock. 2011;35:524-9.
54. Luppi P, Cifarelli V, Tse H, Piganelli J, Trucco M. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-κB pathway. Diabetologia. 2008;51:1534-43.
55. Krishna SV, Kota SK, Modi KD. Glycemic variability: clinical implications. Indian J Endocrinol Metab. 2013;17:611-9.
56. Ido Y, Vindigni A, Chang K, et al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science. 1997;277:563-6.
57. Sima AA, Zhang W, Sugimoto K, et al. C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia. 2001;44:889-97.
58. Redondo MJ, Geyer S, Steck AK, et al; Type 1 Diabetes TrialNet Study Group. A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk. Diabetes Care. 2018;41:1887-94.
59. Redondo MJ, Sosenko J, Libman I, et al. Single islet autoantibody at diagnosis of clinical type 1 diabetes is associated with older age and insulin resistance. J Clin Endocrinol Metab. 2020;105:1629-40.
60. Leslie RD, Evans-Molina C, Freund-Brown J, et al. Adult-onset type 1 diabetes: current understanding and challenges. Diabetes Care. 2021;44:2449-56.
61. Jamiołkowska-Sztabkowska M, Głowińska-Olszewska B, Bossowski A. C-peptide and residual β-cell function in pediatric diabetes - state of the art. Pediatr Endocrinol Diabetes Metab. 2021;27:123-33.
62. Wahren J. C-peptide and the pathophysiology of microvascular complications of diabetes. J Intern Med. 2017;281:3-6.
63. Luppi P, Kallas Å, Wahren J. Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes? Diabetes Metab Res Rev. 2013;29:357-62.
64. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30:803-17.
65. Wahren J, Kallas A, Sima AA. The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes. 2012;61:761-72.
66. Washburn RL, Mueller K, Kaur G, et al. C-peptide as a therapy for type 1 diabetes mellitus. Biomedicines. 2021;9:270.
67. Marques RG, Fontaine MJ, Rogers J. C-peptide: much more than a byproduct of insulin biosynthesis. Pancreas. 2004;29:231-8.
68. Chen J, Huang Y, Liu C, Chi J, Wang Y, Xu L. The role of C-peptide in diabetes and its complications: an updated review. Front Endocrinol. 2023;14:1256093.
69. Alam S, Khan SJ, Lee CYF, Zaidi SAT, Murtaza SF. Type 1 diabetes mellitus management and islet cell therapy: a new chapter in patient care. Cureus. 2023;15:e46912.
70. Bruemmer D. C-Peptide in insulin resistance and vascular complications: teaching an old dog new tricks. Circ Res. 2006;99:1149-51.
71. Walcher D, Babiak C, Poletek P, et al. C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res. 2006;99:1181-7.
72. Maddaloni E, Bolli GB, Frier BM, et al. C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective. Diabetes Obes Metab. 2022;24:1912-26.
73. Otto-Buczkowska E. The clinical utility of C-peptide measurement in diabetology. Pediatr Endocrinol Diabetes Metab. 2015;20:63-8.
74. Mathieu C, Wiedeman A, Cerosaletti K, et al; AG019-T1D-101 Trial Investigators. A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab. Diabetologia. 2024;67:27-41.
75. Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013;56:391-400.
76. Perdigoto AL, Preston-Hurlburt P, Clark P, et al; Immune Tolerance Network. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. 2019;62:655-64.
77. Taylor PN, Collins KS, Lam A, et al; Trial Outcome Markers Initiative collaboration. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. Lancet Diabetes Endocrinol. 2023;11:915-25.
78. Dwyer AJ, Shaheen ZR, Fife BT. Antigen-specific T cell responses in autoimmune diabetes. Front Immunol. 2024;15:1440045.
79. Durinovic-Belló I. Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens. Autoimmunity. 1998;27:159-77.
80. Xie Z, Chang C, Zhou Z. Molecular mechanisms in autoimmune type 1 diabetes: a critical review. Clin Rev Allergy Immunol. 2014;47:174-92.
81. Khosravi-Maharlooei M, Madley R, Borsotti C, et al. Modeling human T1D-associated autoimmune processes. Mol Metab. 2022;56:101417.
82. Yue M, He X, Min X, et al. The role of islet autoantigen-specific T cells in the onset and treatment of type 1 diabetes mellitus. Front Immunol. 2024;15:1462384.
83. Russell WE, Moore DJ, Herold KC. Response to comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013. Diabetes Care. 2023;46:e210-1.
84. Blagov AV, Summerhill VI, Sukhorukov VN, Popov MA, Grechko AV, Orekhov AN. Type 1 diabetes mellitus: inflammation, mitophagy, and mitochondrial function. Mitochondrion. 2023;72:11-21.
85. Basaran E, Aktas G. Waist-to-height ratio as a novel marker of metabolic syndrome in patients with type 2 diabetes mellitus. Explor Endocr Metab Dis. 2025;2:101421.
86. Kosekli MA, Aktas G. The systemic immune inflammation index is a reliable and novel risk factor for metabolic dysfunction-associated fatty liver disease. Curr Med Res Opin. 2025;41:247-51.
87. Czajkowska JB, Shutty B, Zito S. Development of low blood glucose readings in nine non-diabetic patients treated with tumor necrosis factor-alpha inhibitors: a case series. J Med Case Rep. 2012;6:5.
88. Thakkar S, Chopra A, Nagendra L, Kalra S, Bhattacharya S. Teplizumab in type 1 diabetes mellitus: an updated review. touchREV Endocrinol. 2023;19:22-30.
89. Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function. Diabetes Care. 2023;46:1848-56.
90. Orban T, Bundy B, Becker DJ, et al; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412-9.
91. Jasim SA, Yumashev AV, Abdelbasset WK, et al. Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases. Stem Cell Res Ther. 2022;13:101.
92. Loretelli C, Assi E, Seelam AJ, Ben Nasr M, Fiorina P. Cell therapy for type 1 diabetes. Expert Opin Biol Ther. 2020;20:887-97.
93. Wang Z, Xu J, Mo L, et al. The application potential of the regulation of tregs function by irisin in the prevention and treatment of immune-related diseases. Drug Des Devel Ther. 2024;18:3005-23.
94. Bellan M, Andreoli L, Mele C, et al. Pathophysiological role and therapeutic implications of vitamin d in autoimmunity: focus on chronic autoimmune diseases. Nutrients. 2020;12:789.
95. Yan X, Li X, Liu B, et al. Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial. Signal Transduct Target Ther. 2023;8:158.
96. Wang G, Xu J, Ma H, et al. Phenolipid JE improves metabolic profile and inhibits gluconeogenesis via modulating AKT-mediated insulin signaling in STZ-induced diabetic mice. Pharmacol Res. 2023;187:106569.
97. Quarta A, Guarino M, Tripodi R, Giannini C, Chiarelli F, Blasetti A. Diet and glycemic index in children with type 1 diabetes. Nutrients. 2023;15:3507.
